Timothy Eugene Sullivan - 17 Jan 2025 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Chief Financial Officer
Signature
/s/s David Watson, attorney-in-fact for Timothy Sullivan
Issuer symbol
APLS
Transactions as of
17 Jan 2025
Net transactions value
-$51,828
Form type
4
Filing time
21 Jan 2025, 16:11:17 UTC
Previous filing
14 Jan 2025
Next filing
23 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Sale $51,828 -1,730 -2% $29.96 86,370 17 Jan 2025 Direct F1
transaction APLS Common Stock Award $0 +45,929 +53% $0.000000 132,299 21 Jan 2025 Direct F2
holding APLS Common Stock 70,396 17 Jan 2025 The Timothy E Sullivan Irrevocable Trust of 2023 F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This represents shares sold to cover tax withholding on the Restricted Stock Units released on January 16, 2025.
F2 This represents a Restricted Stock Unit award granted on January 21, 2025 that vest 25% annually over four years from grant date subject to continued service.
F3 The securities are held by The Timothy E Sullivan Irrevocable Trust of 2023. Patrick O. Collins is the trustee of The Timothy E Sullivan Irrevocable Trust of 2023. The reporting person disclaims beneficial ownership over the shares held by The Timothy E Sullivan Irrevocable Trust of 2023 except to the extent of his pecuniary interest therein.